Document management in the pharmaceutical industry: Challenges, requirements, and digital solutions

Document management in the pharmaceutical industry represents one of the most heavily regulated and risk-exposed functions across the industrial sector. Every poorly controlled document, every obsolete version consulted on the shop floor, every missing signature or incomplete record can constitute a finding during an FDA inspection, a GMP inspection conducted by a competent European authority, or a client quality audit.

In a pharmaceutical environment, documentation does not merely serve to “prove” that a procedure exists. It must demonstrate that operations are defined, approved, executed, traced, reviewed, and retained according to controlled rules. This is why the requirements of GMP/GMP regulations, FDA 21 CFR Part 11, EU GMP Annex 11, ICH Q10, and the principles of Data Integrity/ALCOA+ are central to any documentation project. FDA 21 CFR Part 11 governs electronic records and electronic signatures subject to FDA regulatory requirements, while EudraLex Volume 4 consolidates the European GMP guidelines, including Chapter 4 dedicated to documentation.

This article explains how to structure reliable pharmaceutical document management, which regulatory requirements to take into account, what limitations paper-based or shared-file approaches present, and how to select a digital solution suited to shop-floor operations.

Key Points Regarding Document Management in the Pharmaceutical Industry :

• Pharmaceutical documentation is subject to precise regulatory requirements: GMP/GMP regulations, FDA 21 CFR Part 11, EU GMP Annex 11, ICH Q10.
• Poor document management can lead to findings during inspections, batch recalls, quality holds, or difficulties with batch release.
• Paper-based or shared-file approaches present structural limitations: fragile version control, uncontrolled access, incomplete traceability, and slow retrieval.
• ALCOA+ principles are essential for demonstrating data integrity in a GxP environment.
• Digitalisation helps standardise procedures, distribute the correct version, trace activities, and collect shop-floor data.
• The choice of solution must incorporate compliance, shop-floor ergonomics, IT integration, hosting, security, system validation, and end-user adoption.

Emmanuel Toulisse, CEO / Co-founder of

LinkedIn Profile:

1. Document Management in the Pharmaceutical Industry: Definition and Critical Challenges

Pharmaceutical document management refers to the totality of processes enabling the creation, revision, approval, distribution, use, archiving, and withdrawal of documents that govern operations. It covers production, quality, maintenance, training, supply chain, procurement, qualification, validation, and quality control activities.

Within GMP/GMP regulations, documentation is a pillar of the pharmaceutical quality system. Chapter 4 of EudraLex Volume 4 is dedicated to documentation and specifies that documents must contribute to demonstrating compliance with GMP requirements.

1.1. Which Types of Documents Are Concerned?

Documents subject to control in a pharmaceutical environment are numerous and heterogeneous. They include notably:

• SOPs — Standard Operating Procedures — and work instructions;
• Batch records and production records;
• Material, product, and equipment specifications;
• Validation protocols and reports;
• Quality control worksheets and audit checklists;
• Training plans and operator qualifications;
• Deviation reports, CAPAs, and change controls;
• Maintenance, cleaning, calibration, and qualification documents;
• Shop-floor forms and execution evidence.

Each category is governed by specific rules for creation, approval, use, and archiving. Document control therefore requires clear governance, a defined document management charter, identified responsibilities, and rigorous version management.

1.2. What Are the Consequences of Poor Document Management?

A documentary failure can trigger severe operational, quality, and regulatory consequences. Among the most frequent risks:

• Use of an obsolete version of a procedure on a production line;
• Inability to reconstruct the history of a batch during an inspection or audit;
• Non-conformance detected during a GMP inspection;
• Traceability gap in a quality decision, deviation, or corrective action;
• Inability to demonstrate operator training;
• Incomplete, illegible, or unattributable data.

These situations are not hypothetical. They directly relate to Data Integrity expectations, commonly summarised by the ALCOA+ principles:

A reliable pharmaceutical record must be attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available.

1.3. Traditional vs. Digital Document Management

Paper-based / shared-file systems vs. adapted pharmaceutical EDMS

Shared files may be sufficient for non-critical documentation. In a pharmaceutical environment, they quickly become inadequate once documents must be validated, traced, consulted on the shop floor, archived, and presented during an audit.

2. Document Management in the Pharmaceutical Industry: Applicable Regulatory Requirements

Regulatory frameworks do not only define what must be documented. They also specify how documents must be created, approved, amended, retained, retrieved, controlled, and made available.

2.1. What GMP/GMP Regulations State About Documentation

Good Manufacturing Practice, as structured in EudraLex Volume 4 for the European Union, devotes an entire chapter to documentation. Chapter 4 specifies that documents must be carefully designed, prepared, reviewed, and distributed, and that they must enable demonstration of compliance with GMP requirements.

The key principles are as follows:

• Documents must be approved, signed, and dated by authorised persons;
• Instructions must be clear, available, and unambiguous;
• Amendments must be controlled, traced, and justified;
• Records must be legible, durable, and accessible;
• Documentation must allow reconstruction of the operations performed;
• Obsolete versions must be withdrawn or clearly identified;
• Documents must underpin the pharmaceutical quality system.

These requirements apply to manufacturers, contract organisations, marketing authorisation holders, and organisations involved in the pharmaceutical supply chain, according to their scope of activity and applicable regulations.

2.2. FDA 21 CFR Part 11 and EU GMP Annex 11: Concrete Implications

• FDA 21 CFR Part 11 governs the use of electronic records and electronic signatures in FDA-regulated industries. It concerns electronic records subject to regulatory requirements and imposes expectations regarding authenticity, integrity, confidentiality, availability, and the control of electronic signatures.
• EU GMP Annex 11 applies to computerised systems used in GMP-regulated activities. It specifies notably that the application must be validated, that the IT infrastructure must be qualified, and that decisions relating to validation controls and data integrity must be grounded in a documented risk assessment.

These texts imply in particular:

• An automatic, comprehensive, and protected audit trail;
• Electronic signatures uniquely linked to their signatory;
• Access control based on defined roles;
• Validation of the computerised system prior to deployment;
• Validation documentation proportionate to risk;
• Clear responsibilities between process owner, system owner, quality, IT, and suppliers;
• The capacity to provide exploitable records during an inspection.

Point of caution: A digital solution does not automatically render an organisation compliant with FDA 21 CFR Part 11 or EU GMP Annex 11. It must be assessed, configured, validated, and operated within the specific context of the organisation.

2.3. ICH Q10 and Documentary Governance

ICH Q10 describes a pharmaceutical quality system model applicable to the development and manufacture of active substances and pharmaceutical products throughout the product lifecycle.

Within this framework, document management must not be treated as a purely administrative function. It underpins:

• Process control;
• Operational reproducibility;
• Change management;
• Personnel training and qualification;
• Deviation and CAPA management;
• Continuous improvement;
• Audit and inspection readiness.

Effective documentary governance must therefore define who drafts, reviews, approves, distributes, withdraws, archives, and controls documents.

3. Document Management in the Pharmaceutical Industry: How to Digitalise Effectively?

What solutions exist for pharmaceutical document management? This question, frequently raised by quality managers and digitalisation project leaders, merits a structured response, since the options are varied and their suitability depends on each organisation’s context.

The following categories are generally distinguished:

• Generalist EDMS (Electronic Document Management Systems);
• QMS platforms;
• Document management modules integrated within ERP, MES, or LIMS systems;
• Solutions specialising in work instructions, SOPs, and shop-floor checklists;
• Hybrid systems combining a centralised EDMS with operational execution tools.

3.1. Where to Begin the Document Digitalisation Process?

Before selecting a tool, it is useful to conduct a documentary baseline assessment. This allows identification of:

• Priority document categories to be brought under control first;
• Existing approval workflows and their degree of formalisation;
• Risk areas: multiple versions, uncontrolled distribution, deficient archiving;
• Critical documents used directly on the shop floor;
• Interfaces with existing systems: ERP, LIMS, MES, QMS, CMMS;
• Applicable system validation requirements;
• Mobile or offline access needs for operators;
• Data collection and execution evidence requirements.

This scoping phase determines the quality of the deployment and the relevance of the documentary governance put in place.

3.2. What Functionalities Must a Solution Suited to Pharma Offer?

An electronic document management system or digital solution adapted to the pharmaceutical environment must cover at minimum:

• Version management with a configurable approval workflow;
• Electronic signatures compliant with applicable requirements;
• Native audit trail, consultable and protected against unauthorised modification;
• Granular access rights management by role, site, department, or document scope;
• Secure digital archiving with configurable retention periods;
• Advanced metadata-based document search;
• Multi-workstation, tablet, or mobile access for shop-floor teams;
• Forms, checklists, and execution evidence management;
• Provision for validation or dual review at critical steps;
• Traceability of consultations, actions, and approvals;
• Exploitable exports for audits or quality reviews.

3.3. Cloud or On-Premise: Which Architecture for a Pharma Documentary Solution?

The choice between cloud, on-premise, or hybrid regularly arises in pharmaceutical projects. It must not be decided on purely technical criteria alone, but on the basis of a risk assessment, quality requirements, IT constraints, and regulatory scope.

In a GMP environment, the architectural choice must be documented. Responsibilities between the software vendor, hosting provider, integrator, internal IT, and quality function must be clearly defined.

4. Pharmaceutical Document Management: Criteria for Selecting a Digital Solution

The market offers a broad spectrum of solutions: generalist EDMS, QMS platforms, tools specialising in shop-floor procedure management, and modules integrated within ERP or MES systems.

The right choice depends on the organisation’s digital maturity, the intended documentary scope, applicable regulatory requirements, IT constraints, and the expected level of shop-floor usage.

4.1. Essential Criteria to Verify Before Selecting

4.2. What Picomto Brings to Pharmaceutical Shop-Floor Teams

Picomto is a solution dedicated to the digitalisation of work instructions, SOPs, checklists, and shop-floor procedures. It features functionalities including checklists, data collection, work instructions, task planning, augmented/mixed reality, and remote assistance, along with use cases covering production, maintenance, and training.

In a pharmaceutical context, Picomto can assist production, quality, maintenance, and methods teams in:

• Standardising and distributing operational procedures in their approved version;
• Making instructions more visual, interactive, and accessible on the shop floor;
• Collecting execution data: forms, photographs, numerical values, validations;
• Monitoring operation execution and generating traceable reports;
• Supporting operator training and qualification;
• Reducing deviations associated with the use of obsolete or poorly understood documents;
• Connecting operational documentation to the existing quality and industrial ecosystem;
• Guiding operators through complex tasks using remote assistance or augmented reality.

Important: Picomto can support document control and shop-floor execution, but final compliance depends on the selected configuration, system validation, internal procedures, access management, and actual usage by teams.

Client example: Haleon and the digitalisation of shop-floor procedures

Haleon, a healthcare sector player, concretely illustrates how the digitalisation of shop-floor procedures can be integrated into a structured quality approach.

Conclusion

Structuring document management in the pharmaceutical industry is not a purely IT project. It is an organisational decision that engages quality, compliance, and operational performance over the long term.

Regulatory requirements define a clear framework: document control, traceability, data integrity, computerised system validation, access control, and record availability. Digitalisation offers concrete levers to address these expectations more effectively, but it does not replace quality governance, validation, or personnel training.

The success of a pharmaceutical documentation project therefore depends on a balance between regulatory requirements, digital maturity, ease of shop-floor use, and the ability to produce reliable evidence during audits and inspections.

FAQ

What is document management?

Document management refers to the totality of processes enabling an organisation to create, validate, distribute, use, update, archive, and control documents throughout their lifecycle. In the pharmaceutical industry, it covers SOPs, work instructions, batch records, validation protocols, quality checklists, and production records.

What is the documentation process in the pharmaceutical industry?

The process generally includes drafting, review, approval, controlled distribution, shop-floor application, update, withdrawal of obsolete versions, and archiving. Each step must be governed by clear responsibilities, validation rules, and traceability compliant with applicable GMP/GMP requirements.

What are the principles of document management?

The principal principles are traceability, uniqueness of the approved version in force, approval prior to distribution, legibility, secure archiving, access control, and data integrity. In a pharmaceutical environment, these principles are closely linked to Data Integrity and the ALCOA+ criteria.

What are the tools for document management?

Available tools range from pharmaceutical EDMS to QMS platforms, including document management modules integrated within ERP, LIMS, or MES systems. For shop-floor teams, specialised solutions such as Picomto enable digitalisation of work instructions, SOPs, checklists, and execution evidence.

What are the objectives of documents in the pharmaceutical industry?

Pharmaceutical documents serve to guarantee the reproducibility of operations, ensure traceability of actions performed, demonstrate compliance with regulatory requirements, support personnel training, and provide exploitable evidence during audits or inspections.

What is the retention period for pharmaceutical documents?

The retention period depends on the nature of the document, the type of product, the relevant market, and applicable regulations. Batch records must generally be retained in accordance with applicable GMP requirements and the organisation’s internal rules. This period must be verified on a case-by-case basis according to the country, product, and applicable regulatory framework.

Does a digital solution guarantee GMP compliance?

No. A digital solution can help strengthen document control, traceability, and version management, but it does not in itself guarantee GMP compliance. Compliance also depends on system validation, internal procedures, access management, training, quality governance, and actual usage by teams.

Key Takeaways :

• Document management in the pharmaceutical industry is a strategic function, directly linked to regulatory compliance, product quality, and operational performance.
• GMP/GMP regulations, FDA 21 CFR Part 11, EU GMP Annex 11, and ICH Q10 impose precise expectations regarding documents, records, versions, electronic signatures, and computerised systems.
• ALCOA+ principles are essential for demonstrating data integrity in a GxP environment.
• The transition to digital helps structure approval workflows, strengthen traceability, and facilitate audit readiness, without replacing organisational rigour.
• The choice of solution must be based on an analysis of documentary scope, risks, required integrations, hosting, validation, and team maturity.
• Shop-floor procedures deserve specific attention: their controlled distribution and execution monitoring are concrete levers for improving operational compliance and reducing deviations.